Compliance-guided therapy: A new insight into the potential role of clinical pharmacologists

Clinical Pharmacokinetics

Volumn 45, Issue 1, 2006, Pages 95-104

  Blesius, Alexia ^a   Chabaud, Sylvie ^a   Cucherat, Michel ^a   Mismetti, Patrick ^b   Boissel, Jean Pierre ^a   Nony, Patrice ^a,c  

^a Cardiovascular Hospital   (France)

^b SERVICE DE NEUROLOGIE   (France)

^c LOUIS PRADEL HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; WARFARIN;

ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ASSAY; GENE SEQUENCE; HUMAN; INDIVIDUALIZATION; MEDICAL PRACTICE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM;

HUMANS; MODELS, BIOLOGICAL; PATIENT COMPLIANCE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; PRACTICE GUIDELINES;

EID: 31344474002     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645010-00007     Document Type: Article

References (43)

1. Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sackett DL, editors. Compliance in health care. Baltimore (MD): Johns Hopkins University Press, 1979: 1
2. Urquhart J. Role of patient compliance in clinical pharmacokinetics: a review of recent research. Clin Pharmacokinet 1994 Sep; 27 (3): 202-15
3. de Klerk E, van der Heijde D, van der Tempel H, et al. Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol 1999 Dec; 26 (12): 2635-41
4. Averbuch M, Weintraub M, Pollack DJ. Compliance assessment in clinical trials: the MEMS device. J Clin Res Pharmacoepi-demiol 1990; 4: 199-204
5. Kruse W, Weber E. Dynamics of drug regimen compliance: its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38 (6): 561-5
6. Urquhart J. Patient non-compliance with drug regimens: mea-surement, clinical correlates, economic impact. Eur Heart J 1996 Mar; 17 Suppl. A: 8-15
7. Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet 1997 May; 32 (5): 345-56
8. Bertholet N, Favrat B, Fallab-Stubi CL, et al. Why objective monitoring of compliance is important in the management of hypertension. J Clin Hypertens (Greenwich) 2000 Jul; 2 (4): 258-62
9. Burnier M, Schneider MP, Chiolero A, et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001 Feb; 19 (2): 335-41
10. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy: an anal-ysis of risk factors. Arch Intern Med 1993 Jul 2; 153 (13): 1557-62
11. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993 Apr 1; 118 (7): 511-20
12. Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993 Sep 2; 329 (10): 696-702
13. Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med 1998 Oct 30; 17 (20): 2313-33
14. Kastrissios H, Suarez JR, Katzenstein D, et al. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 1998 Dec 3; 12 (17): 2295-303
15. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet 1986 Nov-Dec; 11 (6): 483-504
16. Mismetti P, Reynaud J, Laporte-Simitsidis S, et al. Pharmacokinetic and pharmacodynamic variations of acenocoumarol oral-ly administrated either once or twice daily in patients with deep venous thrombosis. Fundam Clin Pharmacol 1998; 12 (6): 631-5
17. Laporte S, Quenet S, Buchmuller-Cordier A, et al. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost 2003 Mar; 89 (3): 458-67
18. Nagashima R, O'Reilly RA, Levy G. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 1969 Jan-Feb; 10 (1): 22-35
19. O'Reilly RA, Aggeler PM, Leong LS. Studies on the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man. J Clin Invest 1963 Oct; 42: 1542-51
20. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharma-cokinet Biopharm 1993 Aug; 21 (4): 457-78
21. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacody-namic data analysis: concepts and applications. Stockholm: Swedish Pharmaceutical Press, 1994
22. Mentre F, Pousset F, Comets E, et al. Population pharmacoki-netic- pharmacodynamic analysis of fluindione in patients. Clin Pharmacol Ther 1998 Jan; 63 (1): 64-78
23. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991 Aug; 84 (2): 527-39
24. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992 Jan 1; 116 (1): 1-5
25. Predictors of thromboembolism in atrial fibrillation: II. Echo-cardiographic features of patients at risk. The Stroke Preven-tion in Atrial Fibrillation Investigators. Ann Intern Med 1992 Jan 1; 116 (1): 6-12
26. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Inves tigators. Arch Intern Med 1996 Feb 26; 156 (4): 409-16
27. Laupacis A, Connolly SJ, Gent M, et al. How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. Ann Intern Med 1991 Nov 15; 115 (10): 818-22
28. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989 Jan 28; I (8631): 175-9
29. Petersen P, Kastrup J, Helweg-Larsen S, et al. Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Arch Intern Med 1990 Apr; 150 (4): 819-21
30. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibril-lation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991 Aug; 18 (2): 349-55
31. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibril-lation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992 Nov 12; 327 (20): 1406-12
32. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993 Nov 20; 342 (8882): 1255-62
33. Morley J, Marinchak R, Rials SJ, et al. Atrial fibrillation, anticoagulation, and stroke. Am J Cardiol 1996 Jan 25; 77 (3): 38-44A
34. The efficacy of aspirin in patients with atrial fibrillation: analy-sis of pooled data from 3 randomized trials. The Atrial Fibrilla-tion Investigators. Arch Intern Med 1997 Jun 9; 157 (11): 1237-40
35. Blakely JA. Anticoagulation in chronic nonvalvular atrial fibril-lation: appraisal of two meta-analyses. Can J Cardiol 1998 Jul; 14 (7): 945-8
36. Hart RG, Benavente O, McBride R, et al. Antithrombotic ther-apy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 Oct 5; 131 (7): 492-501
37. Nony P, Cucherat M, Boissel JP. Revisiting the effect compart ment through timing errors in drug administration. Trends Pharmacol Sci 1998 Feb; 19 (2): 49-54
38. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants: mecha-nism of action, clinical effectiveness, and optimal therapeutic range.Chest 1995 Oct; 108 (4 Suppl.): 231-46S
39. Kumar S, Haigh JR, Rhodes LE, et al. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thromb Haemost 1989 Sep 29; 62 (2): 729-32
40. Kumar S, Haigh JR, Davies JA, et al. Apparent warfarin resis-tance due to poor compliance. Clin Lab Haematol 1989; 11 (2): 161-3
41. Van der Meer FJ, Briet E, Vandenbroucke JP, et al. The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol 1997 Sep; 98 (4): 893-900
42. Reidenberg MM. Evolving ways that drug therapy is individual-ized. Clin Pharmacol Ther 2003 Sep; 74 (3): 197-202
43. Spector R. Optimizing drug therapy. Clin Pharmacol Ther 2004 Jul; 76 (1): 97-8